Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 35.30 CHF | +0.57% | -1.53% | -22.93% | |
| Nov. 20 | Swiss Equities Little Changed Amid Economic Data Spotlight, Julius Bär’s Profit Woes | MT |
| Nov. 20 | Basilea to Get $1 Million Sales Milestone Payment from Pfizer for Antifungal Drug | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Sales 2023 * | 158 M 181 M | Sales 2024 * | 173 M 197 M | Capitalization | 423 M 482 M |
|---|---|---|---|---|---|
| Net income 2023 * | 43.00 M 49.04 M | Net income 2024 * | 55.00 M 62.72 M | EV / Sales 2023 * | 3,02x |
| Net Debt 2023 * | 54.56 M 62.21 M | Net cash position 2024 * | 1.60 M 1.83 M | EV / Sales 2024 * | 2,43x |
| P/E ratio 2023 * | 10,3x | P/E ratio 2024 * | 8,14x | Employees | 143 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 90.06% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.57% | ||
| 1 week | -1.53% | ||
| 1 month | -0.84% | ||
| 3 months | -26.76% | ||
| 6 months | -25.13% | ||
| Current year | -22.93% |
1 week
34.60
36.20
1 month
34.2537.10
Current year
34.2555.40
1 year
34.2555.40
3 years
29.5561.95
5 years
29.2861.95
10 years
29.28139.30
| Managers | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 58 | 2014 |
Adesh Kaul
DFI | Director of Finance/CFO | 49 | 2008 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 59 | 2018 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Skolsky
BRD | Director/Board Member | 67 | 2008 |
Nicole Onetto
BRD | Director/Board Member | 70 | 2017 |
Leonard Kruimer
BRD | Director/Board Member | 65 | 2021 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 175 M€ | +4.97% | - | |
| 0.12% | 509 M€ | +1.98% | ||
| 0.12% | 149 M€ | -.--% | - | |
| 0.06% | 701 M€ | -.--% | - | |
| 0.05% | 97 M€ | +6.07% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-28 | 35.30 | +0.57% | 21,273 |
| 23-11-27 | 35.10 | -0.85% | 25,220 |
| 23-11-24 | 35.40 | -1.12% | 12,685 |
| 23-11-23 | 35.80 | +0.14% | 17,229 |
| 23-11-22 | 35.75 | -0.28% | 14,422 |
Delayed Quote Swiss Exchange, November 28, 2023 at 11:30 am EST
More quotes
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
2024-02-12
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
35.30CHF
Average target price
75.68CHF
Spread / Average Target
+114.38%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -22.93% | 477 M $ | |
| +66.65% | 40 453 M $ | |
| +2.98% | 38 458 M $ | |
| -56.47% | 29 633 M $ | |
| -25.18% | 29 066 M $ | |
| +37.75% | 22 180 M $ | |
| -32.10% | 19 978 M $ | |
| +2.80% | 17 370 M $ | |
| -17.15% | 10 860 M $ | |
| -10.41% | 9 987 M $ |